Clinical Trials in Newport News, Virginia
40 recruiting
Showing 1–20 of 40 trials
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 2
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Hepatocellular Carcinoma
Genentech, Inc.30 enrolled61 locationsNCT06096779
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled243 locationsNCT07136012
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled759 locationsNCT06742723
Recruiting
Phase 3
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
ObesityKnee osteoarthritis (OA)
Novo Nordisk A/S400 enrolled82 locationsNCT07481630
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled452 locationsNCT06531824
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary Biliary Cholangitis
Gilead Sciences318 enrolled196 locationsNCT06051617
Recruiting
Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled845 locationsNCT06307652
Recruiting
Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Hyperlipidemia
Merck Sharp & Dohme LLC975 enrolled89 locationsNCT07216482
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 2
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
Eli Lilly and Company60 enrolled40 locationsNCT07269210
Recruiting
Phase 1Phase 2
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Breast CancerBreast Neoplasms
Pfizer100 enrolled166 locationsNCT06966453
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Hypertension
Eli Lilly and Company974 enrolled100 locationsNCT06948422
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
MASH With FibrosisNASH With Fibrosis
Akero Therapeutics, Inc1,650 enrolled349 locationsNCT06215716
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Hypertension
Eli Lilly and Company487 enrolled99 locationsNCT06952530
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435